Analysis from the EMPA-REG OUTCOME ® trial indicate empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics

In patients with type 2 diabetes mellitus and cardiovascular disease, empagliflozin (EMPA) decreased progression of chronic kidney disease, likely via a reduction in intraglomerular pressure. Due to prevalent comorbidities, such as hypertension and albuminuria, patients often receive other agents that alter intrarenal hemodynamics, including angiotensin converting enzyme inhibitors/angiotensin receptor blockers (ACEi/ARBs), calcium channel blockers and diuretics. Nonsteroidal anti-inflammatory drugs may also be used by some individuals.

Source: Kidney International - March 20, 2019 Category: Urology & Nephrology Authors: Gert J. Mayer, Christoph Wanner, Matthew R. Weir, Silvio E. Inzucchi, Audrey Koitka-Weber, Stefan Hantel, Maximilian von Eynatten, Bernard Zinman, David Z.I. Cherney Tags: Clinical Trial Source Type: research